Cargando…

OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs

Background: Pharmacological targeting aberrant activation of epidermal growth factor receptor tyrosine kinase signaling is an established approach to treating lung adenocarcinoma. Osimertinib is a tyrosine kinase approved and effective in treating lung adenocarcinomas that have one of several common...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kast, Richard E., Halatsch, Marc-Eric, Rosell, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151869/ https://www.ncbi.nlm.nih.gov/pubmed/34068720 http://dx.doi.org/10.3390/cells10051148

Ejemplares similares

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen
por: Kast, Richard E, et al.
Publicado: (2017)

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
por: Kast, Richard E., et al.
Publicado: (2014)

In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma
por: Halatsch, Marc-Eric, et al.
Publicado: (2021)

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen
por: Kast, Richard E., et al.
Publicado: (2022)

The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy
por: Kast, Richard E, et al.
Publicado: (2017)

Antifungal Drug Repurposing
por: Kim, Jong H., et al.
Publicado: (2020)

A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen
por: Kast, Richard E., et al.
Publicado: (2020)

Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
por: Pala, Andrej, et al.
Publicado: (2012)

Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation
por: Kast, Richard E.
Publicado: (2021)

Drug repurposing for neuroregeneration in multiple sclerosis
por: Küry, Patrick, et al.
Publicado: (2018)

Multiple sclerosis drug repurposing for neuroregeneration
por: Göttle, Peter, et al.
Publicado: (2023)

Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
por: Gao, Ya, et al.
Publicado: (2018)

Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology
por: Lythgoe, Mark P., et al.
Publicado: (2022)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
por: Halatsch, Marc-Eric, et al.
Publicado: (2021)

Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen
por: Salacz, Michael E, et al.
Publicado: (2016)

Special Issue: Principal Challenges in the Adjuvant Treatment of Glioblastoma
por: Halatsch, Marc-Eric
Publicado: (2023)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct
por: Söderlund, Johan, et al.
Publicado: (2010)

Repurposing cancer drugs to treat neurological diseases – Src inhibitors as examples
por: Liu, Da Zhi
Publicado: (2017)

Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen
por: Kast, Richard E., et al.
Publicado: (2018)

Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives
por: Pawełczyk, Anna, et al.
Publicado: (2020)

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care
por: Kast, Richard E., et al.
Publicado: (2013)

Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers
por: Kast, Richard E.
Publicado: (2015)

Drug repurposing for the treatment of glioblastoma multiforme
por: Abbruzzese, Claudia, et al.
Publicado: (2017)

Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases
por: Guo, Deyin
Publicado: (2020)

Can Any Drug Be Repurposed for Cancer Treatment? A Systematic Assessment of the Scientific Literature
por: Stransky, Nicolai, et al.
Publicado: (2021)

High Neutrophil-to-Lymphocyte Ratio Facilitates Cancer Growth—Currently Marketed Drugs Tadalafil, Isotretinoin, Colchicine, and Omega-3 to Reduce It: The TICO Regimen
por: Kast, Richard E.
Publicado: (2022)

The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor–Mutated Stage IIIB or IV Non–Small-Cell Lung Cancer Patients
por: Uprety, Dipesh, et al.
Publicado: (2018)

Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy
por: Fan, Yuanyuan, et al.
Publicado: (2022)

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates
por: Rodrigues, Liliana, et al.
Publicado: (2022)

A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing
por: Cabrera-Andrade, Alejandro, et al.
Publicado: (2020)

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020)

Metabolic modeling-based drug repurposing in Glioblastoma
por: Tomi-Andrino, Claudio, et al.
Publicado: (2022)

Repurposing niclosamide for the treatment of neurological disorders
por: Apolloni, Savina, et al.
Publicado: (2023)

Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020)

Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015)

Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma
por: Gao, Zhiqiang, et al.
Publicado: (2020)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iad3di47rkmolnbl2pogcsbol1